Blog: Reflections- Key take outs and reflections from ‘Coffee with Latin America: Telehealth, building a healthier world through technology’
Telehealth is a way we connect and treat when physical meeting is difficult. The benefits and challenges have been thrown into the spotlight even more since the necessity of telehealth through the pandemic.
To discuss this, Coffee With Latin America 'Telehealth, building a healthier world through technology’ was held on the 29th of November 2022. Four speakers from Peru, Colombia, Argentina and Chile shared their experience of using information and communication technology to deliver health services and increase healthcare access.
Farewell to Dr Olive Kobusingye, Distinguished Fellow, retiring from academia
Dr Olive Kobusingye, a renowned trauma surgeon, injury researcher, writer and Distinguished Fellow of The George Institute for Global Health, is retiring from academia at the end of the year. Adding to her existing collaborations with The George Institute in injury prevention, Olive has been a Distinguished Fellow since 2019. We are grateful for Olive’s passion for sharing knowledge, her collaborative spirit, and her contribution to capacity strengthening.
Healthier societies: Professor Kent Buse on tackling health and gender inequality
Professor Kent Buse, Co-founder and Co-director of Global Health 50/50, discusses the relationship between gender and health inequality. Alongside fellow Co-founder and Co-director, Professor Sarah Hawkes, Buse is leading the independent initiative to actively assess global health organisations on their gender equality credentials to stamp out discriminatory policies and practices. Buse is also the Director of the Global Healthier Societies Program at The George Institute for Global Health. ‘Fixing systems, not people’, the programme aims to go beyond the provision of basic healthcare, advocating research-based interventions to help people enjoy lifelong good health.
Study reveals recommended anti-clotting therapy for COVID patients
The AustralaSian COVID-19 Trial (ASCOT) has pinpointed the most efficient level of blood thinning treatment needed for patients hospitalised with COVID-19.